ALSO NOTED: Perlegen files $115M IPO; Pharmacyclics acquires cancer treatment candidates from Celera; and much more...

> Preliminary Phase III data of Myogen's Ambrisentan demonstrated that the drug improved the ability of patients suffering from pulmonary arterial hypertension to exercise. Report

> Bayer Healthcare and Nuvelo have initiated a second Phase III trial of Alfimeprase. Release

> Atlanta-based Corautus Genetics has terminated enrollment in its Phase IIb clinical trial based on the recommendation of its independent Data Monitoring Committee. The DMC saw little chance for significant efficacy compared to the safety risk involved. Release

> Perlegen Sciences is planning an IPO of as much as $115 million in common stock. Report

> Pharmacyclics has acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics. Report

> Somaxon Pharmaceuticals announced positive results from its initial Phase III clinical trial Silenor, a treatment for chronic insomnia. Release

And Finally... A fat-burning laser could offer some hope to those with cellulite and acne. Article